Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重点成果- 年内，集团共有4个创新产品获NMPA批准上市，分别为赛坦欣(R)（库莫西利胶囊）、圣赫途(R)（宗艾替尼片）、普坦宁(R)（美洛昔康注射液(II)）和安启新(R)（注射用重组人凝血因子VIIa N01）。- 2025年，集团创新产品收入达到人民币152.2亿元，同比增长26.2%。此外，集团已在上海、南京、北京、广州等地建立多个研发中心，并成功构建了涵盖小分子、蛋白降解剂、siRNA、单抗／双抗、抗体偶联药物（ADC）、吸入制剂、透皮贴剂等领域的多元化创新技术平台。- 截至2025年12月31日，集团共有39个肿瘤领域、10个肝病╱心血管代谢领域、14个呼吸╱自免领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，1个肿瘤领域、2个外科╱镇痛领域产品处在上市申请阶段；13个肿瘤领域、1个肝病╱心血管代谢领域、5个呼吸╱自免领域、1个外科╱镇痛领域的创新候选药物处于临床III期，9个肿瘤领域、6个肝病╱心血管代谢领域、5个呼吸╱自免领域、2个外科╱镇痛领域的创新候选药物处于临床II期，另有16个肿瘤领域、3个肝病╱心血管代谢领域、4个呼吸╱自免领域、1个外科╱镇痛领域的创新候选药物处于临床I期。- 福可维(R)（盐酸安罗替尼胶囊）是一款新型小分子多靶点酪氨酸激酶抑制剂，目前已获批10项适应症，其一线非鳞状非小细胞肺癌、一线胰腺癌等多项新适应症正在开展III期临床研究，预计未来两年将逐步递交上市申请。- 2023-2025年，集团共有7款肿瘤领域的国家1类创新药获批上市，分别为：赛坦欣(R)（库莫西利胶囊）、圣赫途(R)（宗艾替尼片）、亿立舒(R)（艾贝格司亭α注射液）、安得卫(R)（贝莫苏拜单抗注射液）、安柏尼(R)（富马酸安奈克替尼胶囊）、安洛晴(R)（枸橼酸依奉阿克胶囊）和安方宁(R)（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯(R)（贝伐珠单抗注射液）、得利妥(R)（利妥昔单抗注射液）、赛妥(R)（注射用曲妥珠单抗）和帕乐坦(R)（帕妥珠单抗注射液）。该等产品在2025年快速放量，成为集团收入增长的重要贡献品种。- 天晴甘美(R)（异甘草酸镁注射液）是第四代甘草酸制剂，目前已获批3个适应症。集团年内着力加强学术推广，透过各层级的学术会议增强了医生覆盖和专家认可，同时大力发掘新患者拓展新市场，并积极推进回顾性研究，为其临床使用提供更多的学术证据。- TQC3721（PDE3／4抑制剂）是一款PDE3／4双重抑制剂，目前正在中国开展III期临床试验，用于治疗中重度慢性阻塞性肺病（COPD）。集团正在开发TQC3721的多种剂型：吸入用混悬液位于III期临床阶段，吸入粉雾剂位于II期临床阶段，有望透过多种剂型进一步提升患者的依从性。- 泽普思(R)／得百安(R)（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思／得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在年内获批上市，透过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年12月31日止12个月（「年内」）之经审核财务业绩。年内，集团收入增长约10.3%至约318.3亿元（人民币，下同）。来自持续经营业务之归属于母持有者盈利（财务报表所示）约23.4亿元，按年增长约22.0%。来自持续经营业务之归属于母公司持有者盈利计算之每股基本盈利约人民币13.02分，较去年增加约24.0%。归属于母公司持有者之基本溢利约45.4亿元，按年增长约31.4%。集团流动资金保持充裕，年内有计入流动资产之现金及银行结余约121.8亿元、计入非流动资产之银行存款约102.5亿元，理财管理产品总额约105.6亿元，资金储备总额约329.9亿元。董事会建议派发末期股息每股5港仙（2024年：4港仙），连同已派发中期股息每股5港仙，全年合共派发股息每股10港仙（2024年：7港仙）。销售：创新引领，销售动能持续释放年内，集团持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。年内，创新产品之收入同比增加26.2%，达约152.2亿元。至于分治疗领域，抗肿瘤用药之收入同比增加22.8%，达约131.8亿元，占集团收入约41.4%。外科／镇痛用药之收入同比增加12.8%，达约50.3亿元，占集团收入约15.8%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，福可维(R)（盐酸安罗替尼胶囊）已获批10项适应症，多项新适应症处于上市申请或III期临床阶段，其联合疗法在肺癌治疗中展现出优效。2023年至2025年间，集团共有7款肿瘤领域的国家1类创新药以及4款肿瘤领域的生物类似药获批上市，该等产品在2025年快速放量，成为集团收入增长的重要贡献品种。于外科╱镇痛领域，泽普思(R)／得百安(R)（氟比洛芬凝胶贴膏）连续多年蝉联外用镇痛市场份额第一位，第二代氟比洛芬贴剂预计将在年内获批上市，有望透过剂型升级巩固市场领先地位。同时，中国首款一日一次长效镇痛NSAIDs注射液普坦宁(R)（美洛昔康注射液（II））已于2025年5月获得NMPA和FDA的上市批准，并已被新增纳入2025年国家医保药品目录，有望成为集团镇痛领域的又一款重磅产品。研发：技术筑基，研发质效显著提升研发创新始终是集团的核心驱动力，集团目前已在上海、南京、北京、广州等地建立多个研发中心，并成功构建了涵盖小分子、蛋白降解剂、siRNA、单抗／双抗、抗体偶联药物（ADC）、吸入制剂、透皮贴剂等领域的多元化创新技术平台。截至二零二五年十二月三十一日止年度，研发总投入约人民币63.2亿元，占集团收入约19.8%。集团亦重视保护知识产权，积极申报各项专利，以提高核心竞争力。年内，集团提交专利申请1,167项、获得专利授权273项。截至年末，集团累计有效专利申请达5,724项，累计有效专利授权达2,120项。展望：聚焦创新，坚定推进国际化战略展望未来，集团将继续聚焦创新，深耕肿瘤、肝病／心血管代谢、呼吸／自免、外科／镇痛四大核心治疗领域，以AI深度赋能研发全流程，持续强化创新研发能力推动业绩稳步增长。预计未来三年（2026-2028年），集团创新管线将迎来新一轮爆发式增长，预计近20款国家1类创新药有望获批上市，涵盖多款具备全球同类首创 (FIC) ／同类最佳 (BIC) 潜力的重磅产品。预计至2028年底，集团上市创新产品总数将达到近40款，成为驱动业绩增长的核心引擎。同时，集团坚定推进国际化战略。2026年2月，集团宣布授予Sanofi在全球范围内开发、生产及商业化罗伐昔替尼的独家许可，并有权获得最高15.3亿美元的付款，以及基于罗伐昔替尼年度净销售额的高达双位数的销售提成。未来，对外授权合作将成为集团的又一重要收入来源，持续为业绩增长注入强劲新动能，正式开启以国际化收入为支撑的第二增长曲线。此外，集团始终秉持「合作共赢」理念，着力构建开放多元的创新生态体系。透过与全球顶尖药企、生物科技公司及科研机构的深度合作，集团正加速汇聚全球优质资源，推动创新成果的共创共享，持续巩固市场领导地位。透过整合礼新医药、赫吉亚等优质资源，集团在肿瘤免疫及siRNA等前沿赛道的研发实力显著增强。未来，集团将继续以自主研发与战略合作双引擎驱动创新，以国际化加速发展，向世界级创新医药企业的战略目标稳步迈进。有关集团本年度详细业绩资料，请参阅集团上载至香港联合交易所及官网之正式公告。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病／心血管代谢、呼吸／自免、外科／镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sbpgroup.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州西棕榈滩, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 作为1890年成立的美国马球协会（USPA）官方运动品牌，U.S. Polo Assn. 今日宣布启动其全球马球衫宣传活动——“源自赛场的经典”。此次全球宣传活动旨在向标志性的马球衫致敬，既彰显其纯正的运动血统，也展现其演变为全球最具持久魅力的时尚单品之一的过程。U.S. Polo Assn. 全球品牌大使、6级美国职业马球运动员尼科·埃斯科巴（Nico Escobar）身着马球白装及经典海军蓝 U.S. Polo Assn. 马球衫，骑着爱驹观赛，演绎“源自赛场的经典”U.S. Polo Assn. 模特身着马球衫，亮相于南卡罗来纳州查尔斯顿举办的2026春夏全球系列大片拍摄现场以U.S. Polo Assn.模特为主角的“Polo衫：源自赛场的经典”宣传大片Polo衫的起源可追溯至马球赛场，它由运动、竞技以及其命名所源自的马球精神所塑造。自诞生之初，Polo衫便以功能性为设计核心，专为追求赛场表现的马球运动员而打造。如今，U.S. Polo Assn. 致敬这款永恒经典，它不仅是一件时尚单品，更是源自体育运动、经由世界各地数代运动员与消费者传承至今的标志性象征。Polo衫是拥有逾百年历史的最具标志性的经典单品之一，以其运动与时尚的独特融合而著称。最初采用透气的平纹针织面料、柔软的领口和轻盈的结构设计，以满足竞技运动的需求，如今它已演变为一款永恒的经典单品，既适合展现休闲优雅，也适合日常休闲穿着。Polo衫的起源可追溯至马球运动员，其诞生源于运动的实际需求。马球运动员曾对长袖棉质衬衫进行改良，以更好地应对比赛中的高温、动作和风力。这些功能性、运动驱动的改良，正是后来Polo衫的雏形。20世纪初，随着马球运动日益普及，马球运动员们将这些功能性元素正式确立下来，从而强化了Polo衫与这项运动及其功能性设计的紧密联系。多年来，Polo衫已成为全球休闲运动装的基石，象征着学院风、奢华休闲文化以及当代运动休闲风，从马球场到大学校园再到董事会会议室，其风格转换自如。数十年来，Polo衫历经多次独特革新，彰显了其持久的适应性；这种不断演变的能力，确保了Polo衫经久不衰的时尚地位和文化意义。作为成立于1890年、美国历史最悠久的体育管理机构之一——美国马球协会（USPA）的官方运动品牌，U.S. Polo Assn.在马球衫的历史长河中占据着无可替代的地位。“马球衫的基因深深植根于孕育它的这项鼓舞人心的运动之中，”USPA Global总裁兼首席执行官J. Michael Prince表示。该公司负责管理和推广价值数十亿美元的全球性品牌U.S. Polo Assn.。“通过‘源自赛场的传奇’这一主题，我们致敬了始于赛场、并持续塑造着当今乃至未来几代马球运动员、体育迷和消费者生活方式、行动方式及自我表达方式的传承。”“源自赛场的传奇”通过将马球衫与马球运动的起源相联结，同时颂扬其在现代文化中的地位，从而进一步强化了这一传承。“马球衫最初是为比赛设计的，在赛场上有着切实的用途，但它也是我场下外出就餐或与亲朋好友聚会时的日常穿搭，”U.S. Polo Assn. 全球品牌大使、6级美国职业马球运动员尼科·埃斯科巴说道，“我很欣赏U.S. Polo Assn. 既注重性能表现，又懂得如何将马球衫融入日常生活。”“U.S. Polo Assn. 与马球运动的深厚渊源，以及它对全球马球运动的支持，正是我无论在赛场内还是赛场外都选择穿着它的原因，”埃斯科巴补充道。全球发布：源自赛场的经典“源自赛场的经典”系列将于2026年春季在全球190个国家同步上市。通过精心策划的多渠道整合营销，该系列将生动呈现，确保无论消费者在何处接触这个运动灵感品牌，都能清晰辨识出U.S. Polo Assn.的马球衫。在实体店中，专门的马球衫展示区——包括品牌标志性的马球墙、橱窗陈列及视觉营销亮点——将通过大胆的色彩搭配、清晰的分类以及以口号为核心的宣传标识，全面展示全系列款式。在户外及平面广告中，实地拍摄的主视觉画面将马球衫带回赛场，强化了其与这项运动的真实联系；而数字及社交媒体营销活动则通过短视频内容和全球化叙事延伸这一故事。这些触点共同构成了一个连贯且沉浸式的表达，展现了马球衫作为真正标志性单品的特质——它植根于体育运动，却又与日常生活息息相关。此外，“源自赛场的标志”营销活动将围绕美国马球界两大重要赛事展开——享有盛誉的USPA金杯赛®以及全球竞争最激烈的赛事之一——美国马球公开赛®，该赛事将于4月26日迎来冠军决赛。“‘源自赛场的经典’旨在彰显我们的真实本色，并以大胆姿态向全球讲述这一故事，”全球品牌营销副总裁斯蒂芬妮·科罗亚莱斯（Stefanie Coroalles）表示。“此次全球Polo衫宣传活动将品牌传承、产品与自我表达融为一体，展现了Polo衫如何从运动场无缝融入日常生活。”“此次发布令我们倍感自豪，它以一种现代、醒目且不折不扣的U.S. Polo Assn.风格，让我们的品牌传承焕发新生，”科罗亚莱斯补充道。产品核心理念：随心演绎“每一件 U.S. Polo Assn. polo 衫都经过精心设计，在风格、舒适度、功能性以及正宗的运动细节之间取得了完美平衡，”品牌与产品开发高级副总裁布莱恩·卡米纳（Brian Kaminer）表示。“从受传统启发的剪裁到现代功能性面料，我们的 U.S. Polo Assn. 系列展现了 polo 衫在忠于其运动本源的同时，如何不断演变。”此次全球马球衫宣传活动通过五种截然不同的风格诠释，展现了这一经典单品的百搭特性，让消费者在搭配马球衫时能够“随心而动”。“运动风”系列马球衫的每一针一线都承载着U.S. Polo Assn.的传承。凭借正宗的细节处理、标志性的品牌标识以及运动灵感元素，这款永恒的剪裁设计直接呼应了品牌起源的马球运动。官方徽章、经典剪裁与传统设计细节，共同致敬马球运动的历史与品牌深厚的传承。“经典风范”系列专为日常生活的点滴时刻而生。简约、舒适且易于搭配，是您追求百搭之选时的首选。这款设计旨在经久耐穿，无论休闲、惬意还是稍显正式的场合，都能完美融入您的日常穿搭。Play It in Motion 系列专为动态活动打造的高性能POLO衫。采用先进技术面料，具备吸湿排汗、透气舒适及弹性伸展特性，全天候随您自由活动。无论是在赛场上还是生活中，这款专为POLO球手设计的POLO衫，在兼顾耐用性与功能性的同时，更呈现出利落现代的造型。Play It Bold 系列是专为自我表达而生的时尚POLO衫。这款POLO衫以自信与风格为特质，为经典单品注入个性与自由。无论是随性穿着还是精心搭配，它都展现了当Polo衫由自信塑造、并按个人方式穿出时，其多变的魅力。Play It Elevated是专为需要精致时刻打造的顶级Polo衫。采用高级面料与精心细节，呈现出精致外观却不显拘谨。简洁的线条与考究的剪裁，营造出从容而自信的风格，在舒适与优雅之间取得完美平衡。U.S. Polo Assn.本季的Polo衫涵盖男装、女装及童装系列，面料、工艺与色彩选择丰富多样——从经典中性色到鲜艳亮色应有尽有。新款设计融入了纹理罗纹、低调图案及精湛的工艺细节，并饰有品牌标志性的双骑士徽标——既是正品的印记，也是这项运动的象征。U.S. Polo Assn. 持续推出符合其全球可持续发展计划“USPA Life”的产品，彰显了品牌对负责任采购及长期环保举措的承诺。将于2027年春季登陆门店的“USPA Life”Polo衫，以U.S. Polo Assn.最具标志性的款式为基础，采用精心挑选的优质面料，体现了品牌致力于改善这款经典单品对全球环境影响的承诺。从100%优质棉面料到纽扣、缝线等细节处理，每个元素的选用都旨在减少环境影响，同时保留顾客对U.S. Polo Assn.马球衫所期待的经典外观、舒适度与品质。U.S. Polo Assn.的服装及配饰可在U.S. Polo Assn.门店及官网uspoloassnglobal.com购买。关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会（USPA）的官方运动品牌。USPA 成立于 1890 年，是美国规模最大的马球俱乐部和马球运动员协会。U.S. Polo Assn. 业务规模达数十亿美元，通过全球1,200多家零售店及数千个其他销售网点进行分销，为全球190多个国家的男女及儿童提供服装、配饰和鞋履。该品牌赞助了全球各大马球赛事，包括每年在棕榈滩的NPC举行的美国公开马球锦标赛®——这是美国最顶级的马球锦标赛。通过与美国ESPN、欧洲TNT和Eurosport以及印度Star Sports达成的历史性合作，由U.S. Polo Assn.赞助的数项世界顶级马球锦标赛现已实现电视转播，使全球数百万体育迷首次得以欣赏这项激动人心的运动。根据《License Global》的报道，U.S. Polo Assn. 一直与 NFL、PGA 巡回赛及一级方程式赛车并列为全球顶尖的运动授权商之一。此外，这个以运动为灵感的品牌更因全球业务成长及运动内容而获得国际奖项肯定。凭借其作为全球品牌的巨大成功，U.S. Polo Assn. 曾获《福布斯》、《财富》、《现代零售》及《GQ》等媒体报道，并登上雅虎财经与彭博社等全球众多知名媒体平台。欲了解更多资讯，请造访 uspoloassnglobal.com 并追踪 @uspoloassn。USPA Global 是美国马球协会（USPA）的子公司，负责管理市值数十亿美元的运动品牌 U.S. Polo Assn.。USPA Global 同时管理其子公司 Global Polo，该公司是全球马球运动内容的领导者。欲了解更多资讯，请造访 globalpolo.com 或 YouTube 上的 Global Polo 频道。如需更多资讯，请联系：Stacey Kovalsky - 全球公关与传播副总裁电话 +954.673.1331 - 电子邮件：skovalsky@uspagl.com Kaela Drake - 高级公关与传播专员电话 +561.530.5300 - 电子邮件：kdrake@uspagl.com 消息来源：U.S. Polo Assn. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 26, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is pleased to announce that it has received a large dataset of historic drill hole information from the Congress Gold Mine Project in Yavapai County, Arizona, USA. Comprehensive desktop technical studies integrating this data with the Company's own 2022 drilling campaign have resulted in the identification and delineation of three distinct priority exploration zones that will form the basis of the 2026 field and drilling program.HIGHLIGHTSReceipt of a large historic drill hole database greatly expanding the geological model for the Congress Gold Mine Project3D modelling of over 100 historic and recent drill holes confirms strong structural integrity and continuity of the gold-bearing vein systemsThree distinct exploration zones classified: Echo Bay Exploration Zone (~750m x 1,000m), Malartic Exploration Zone (~450m x 1,150m), and New Congress Niagara Exploration Zone (~800m x 1,000m)Echo Bay Exploration Zone designated highest priority target based on historic drill density and potential for expanded mineralization envelopeHistoric drill intercepts include highlights such as 1.2m @ 43.88 g/t Au, 2.0m @ 21.88 g/t Au, 3.3m @ 27.13 g/t Au, and 11.4m @ 4.81 g/t Au within the Echo Bay ZoneCongress Gold Mine Project is fully permitted with excellent road access and proximity to an experienced regional labor forceCompany geologists and field personnel are being mobilized for initial site preparation and drill program setupHISTORIC DRILL DATABASE COMPILATIONCasa Minerals is pleased to announce the receipt of a comprehensive dataset of historic drill hole collars, surveys, and assay records from the Congress Gold Mine Project. This data was compiled from exploration programs conducted by previous operators -- most notably Echo Bay Mines Ltd. -- during the 1980s through the early 1990s. The database encompasses a significant number of drill holes distributed across the project area, substantially expanding the known geological framework of the property.Historic exploration at the Congress Gold Mine was conducted during a period when gold market conditions were materially lower than today's environment, which directly influenced the selection criteria and cut-off grades used by previous operators. Consequently, the historic programs focused predominantly on higher-grade gold intersections, and many lower-grade vein intercepts that may be economically significant at current gold prices were not assigned the same level of analytical priority. Casa believes this creates a meaningful opportunity to reinterpret the mineralization system with a lower economic threshold, logically expanding the dimensions of the mineralization envelope that will be targeted in the forthcoming drilling season.Important Disclosure: The historic drill hole results referenced in this news release were collected and reported by previous operators under practices that predate current NI 43-101 standards. These results are disclosed solely for contextual and geological interpretation purposes. They have not been verified by a current Qualified Person, do not conform to NI 43-101, and are not classified as current mineral resources or mineral reserves. A Qualified Person has not done sufficient work to classify the historic results as current mineral resources or mineral reserves, and Casa is not treating them as such.THREE-DIMENSIONAL MODELLING AND VEIN SYSTEM VALIDATIONDesktop technical studies have included rigorous 3D modelling of all available drill hole data using industry-standard geological modelling software. The resulting three-dimensional representation of the drill hole database, illustrated in Figure A below, demonstrates the remarkable density of historic drill coverage across the project and confirms the structural coherence and continuity of the principal gold-bearing vein systems.The 3D model was constructed using NAD83 / UTM Zone 12N coordinates and captures drill holes ranging from surface to depths approaching 600 metres below ground elevation. The model reveals that:The dominant vein systems exhibit strong northeast-southwest structural orientation, consistent with the principal fault architecture identified on surfaceThe alignment and attitude of vein structures intercepted in the Company's 2022 confirmatory drilling campaign correlate with high fidelity to those projected from the historic drill hole database, validating the overall geological modelThe 2022 drilling campaign identified additional vein structures not captured in the historic database, indicating that the current geological model is likely incomplete and that the total mineralized footprint may be materially larger than previously understoodIncorporating lower-grade vein intercepts -- previously deprioritized by historic operators under lower gold price conditions -- into the mineralization envelope substantially increases the aggregate target volume for future drillingFigure A: Four-panel 3D presentation of historic and recent drill hole collars and traces, Congress Gold Mine Project. Views from west (upper left), east (upper right), oblique (lower left), and plan (lower right). Coordinate system: NAD83 / UTM Zone 12N. The high density of drill traces illustrates the extensive historic exploration coverage across the project area. Pink/magenta traces represent historic drill holes; black traces represent more recent drilling. Purple lines denote projected vein orientations.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_001full.jpgTHREE PRIORITY EXPLORATION ZONES -- 2026 PROGRAM BASISDetailed integration of the historic drill database with geological mapping, vein system mapping conducted in 2022, and structural interpretation has enabled Casa to formally classify three distinct priority exploration zones within the Congress Gold Mine Project. The classification of each zone reflects the combination of historic drill density, vein system geometry, and the nature of the gold mineralization documented to date. Figures 1 through 4 present these zones in their regional and local contexts.Figure 1: Regional overview map of the Congress Gold Mine Project showing principal vein systems (red dashed), fault corridors (blue dashed), shaft locations (Shafts 1 through 6), historic stope outlines (yellow, 1959-1987), patented claim and BLM claim outlines, and the location of the three principal exploration zones. The project is situated in Yavapai County, Arizona.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_002full.jpgEcho Bay Exploration Zone -- Highest Priority TargetThe Echo Bay Exploration Zone, measuring approximately 750 metres by 1,000 metres, is the largest and most intensively drilled zone on the property. It encompasses the historic non-NI 43-101 resource outline that was previously defined by Echo Bay Mines and represents the core of the historic gold-producing system at Congress. The zone is bounded by the principal northeast-trending veining corridors and is cut by northwest-trending fault structures that locally displace but do not terminate the mineralized vein arrays.As illustrated in Figure 2, the Echo Bay Exploration Zone hosts a dense cluster of historic drill hole intercepts distributed across the full extent of the zone. The drill hole collars and assay intercepts depicted in the figure provide compelling evidence for broad, zone-scale gold mineralization. Notably, the higher-grade intercepts are concentrated along the principal vein corridors while lower-grade disseminated and stockwork gold is documented in the intervening ground. This spatial distribution is characteristic of orogenic gold systems and is consistent with the geological setting at Congress.Selected historic drill intercepts within the Echo Bay Exploration Zone include:1.2m @ 43.88 g/t Au -- exceptional high-grade intercept within the principal vein corridor3.3m @ 27.13 g/t Au -- high-grade intercept demonstrating vein width and continuity2.0m @ 21.88 g/t Au -- high-grade vein intercept in the central portion of the zone2.4m @ 19.03 g/t Au -- confirming strong grade continuity along strike11.4m @ 4.81 g/t Au -- broad, elevated-grade intercept indicative of wide mineralization envelopes within the vein system1.5m @ 15.28 g/t Au -- demonstrating high-grade vein core and broader lower-grade haloes2.0m @ 12.19 g/t Au and 7.3m @ 11.00 g/t Au -- further confirming grade and continuity of the principal vein arrays3.1m @ 11.19 g/t Au and 2.0m @ 15.63 g/t Au -- documented in the southwestern portion of the zone, indicating lateral continuityGiven the historic drill density, the documented grade profile, and the alignment of the 2022 confirmatory drilling with the historic vein model, the Echo Bay Exploration Zone has been assigned the highest exploration priority for the 2026 program. The Company views the zone as offering the clearest near-term pathway to NI 43-101 resource delineation.Figure 2: Detailed plan map of the Echo Bay Exploration Zone (~750m x 1,000m), Congress Gold Mine Project. Shown are historic drill hole intercepts (brown dots annotated with interval length in metres and gold grade in g/t), principal vein system traces (red dashed), fault corridors (blue dashed), historic stope outlines (yellow), shaft locations, and the historic non-NI 43-101 resource outline (red hatch). Selected intercepts include 1.2m @ 43.88 g/t Au, 3.3m @ 27.13 g/t Au, 11.4m @ 4.81 g/t Au, and 2.4m @ 19.03 g/t Au, among numerous others. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_003full.jpgMalartic Exploration ZoneThe Malartic Exploration Zone covers an area of approximately 450 metres by 1,150 metres and is situated to the south and southeast of the Echo Bay Exploration Zone. The zone is named after the "Malartic-style" stratabound and vein-hosted gold mineralization that has been documented in this area of the project. Historic shaft locations CGC-003 and CGC-004 are located within this zone, providing direct underground access for potential future development.The Malartic Exploration Zone is characterized by multiple subparallel northwest-striking vein sets that have been intercepted in a series of shallow to moderate-depth drill holes. The vein system includes documented vein widths of 27 feet, 38 feet, and 55 feet (as labelled on Figure 3), indicating substantial structural corridors capable of hosting economically significant gold mineralization.Representative historic drill intercepts within the Malartic Exploration Zone include:3.6m @ 0.74 g/t Au and 10.3m @ 1.73 g/t Au -- broad lower-grade intercepts within the principal vein corridor demonstrating wide mineralization envelopes10.36m @ 1.41 g/t Au and 8.1m @ 3.53 g/t Au -- moderate-grade intercepts confirming continuity of the vein arrays7.7 @ 3.56 g/t Au and 8.1m @ 2.53 g/t Au -- further demonstrating consistent grade within vein-hosted mineralization3.2m @ 7.72 g/t Au and 2.8m @ 9.41 g/t Au -- higher-grade intercepts at the northern margin of the zone (shared boundary with the Echo Bay Zone)The Malartic Exploration Zone is relatively underexplored compared to the Echo Bay Zone, and the relatively sparse drill coverage suggests significant upside potential for zone expansion with systematic drilling.Figure 3: Detailed plan map of the Malartic Exploration Zone (~450m x 1,150m), Congress Gold Mine Project. Shown are historic drill hole intercepts (annotated with gold values), principal vein system traces, shaft locations including CGC-003 and CGC-004, historic stope outlines, and documented vein widths of 8.2m, 11.6m, and 16.8m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_004full.jpgNew Congress Niagara Exploration ZoneThe New Congress Niagara Exploration Zone, measuring approximately 800 metres by 1,000 metres, is the northernmost of the three classified exploration zones and is situated along a structurally distinct corridor characterized by the northwest-striking New Congress-Niagara fault system. This zone encompasses historic Shaft 1 as well as drill holes CGC-008, CGC-009, and CGC-010 from the Company's 2022 exploration program.The 2022 drilling in this zone identified four discrete veins with widths ranging from 49.5 feet to 206 feet -- a notably wide structural corridor. These widths are illustrated in Figure 4 as Vein 49.5 ft, Vein 55 ft, Vein 70.5 ft, and Vein 206 ft. The scale of these structural features highlights the potential for significant bulk-tonnage style mineralization within this zone, distinct from the higher-grade but narrower veins documented in the Echo Bay Zone.Critically, the 2022 drilling at the New Congress Niagara Zone identified several vein structures that are not represented in the historic drill database, reinforcing the Company's view that the existing geological model incompletely captures the full scope of the vein system. This structural incompleteness, combined with the relatively limited historic drill coverage of this zone, underscores its exploration potential.Figure 4: Detailed plan map of the New Congress Niagara Exploration Zone (~800m x 1,000m), Congress Gold Mine Project. Shown are drill hole locations from the 2022 exploration program (CGC-008, CGC-009, CGC-010) alongside Shaft 1, with identified vein widths of 49.5 ft, 55 ft, 70.5 ft, and 206 ft. The purple outline denotes the exploration zone boundary.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_005full.jpgPROJECT STATUS AND 2026 FIELD PROGRAMThe Congress Gold Mine Project is fully permitted for exploration and mining activities in Yavapai County, Arizona. The property benefits from:Fully permitted status: All necessary exploration and access permits are in place, enabling rapid mobilization of field crews and drilling equipmentExcellent road access: Paved and maintained road access to the property boundary facilitates cost-effective equipment and supply logisticsExperienced regional labor force: The Yavapai County region has a well-established mining and exploration workforce with proven experience in gold exploration projects of this typeInfrastructure: Existing shaft infrastructure and historic workings provide geological reference points and potential future development opportunitiesThe Company is currently mobilizing a team of geologists and field personnel to the Congress Gold Mine Project for initial site preparation, geological review, and establishment of the field infrastructure required for the 2026 drilling program. Detailed drill program parameters, including planned hole locations, depths, and targeting rationale, will be provided in a subsequent technical news release.MANAGEMENT COMMENTARY"The receipt of this historic drill database is a genuinely significant development for Casa Minerals," stated Farshad Shirvani, President and CEO. "For the first time, we now have a comprehensive view of the full scope of historic exploration at Congress, and what we see is highly encouraging. The 3D model clearly validates our 2022 findings and demonstrates that the gold system is both continuous and larger than historic estimates suggested. With gold trading at current levels, the lower-grade vein intercepts that were historically deprioritized now become compelling exploration targets in their own right. The Echo Bay Zone, with intercepts like 1.2m @ 43.88 g/t and 11.4m @ 4.81 g/t, gives us a very strong foundation from which to build a modern NI 43-101 resource. We are mobilizing our team and look forward to reporting our first drill results from the 2026 season."QUALIFIED PERSONMr. Erik Ostensoe, P.Geo., a Director and Chief Geologist of the Company, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure in this news release.ABOUT CASA MINERALS INC.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the Company's exploration plans and programs for 2026; anticipated drilling activities at the Congress Gold Mine Project; the classification and prioritization of exploration zones; expectations regarding resource definition and the potential to advance the project to NI 43-101 compliant standards; interpretations of historic drill data and 3D geological models; mineralization potential and domain expansion; and mobilization of field personnel. Forward-looking information is based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated. Such factors include, without limitation: uncertainties regarding exploration results; risks related to the accuracy and completeness of historic data; the inability to verify historic assay results; variations in mineralization and grade; the speculative nature of mineral exploration; challenges in obtaining required permits and approvals; fluctuations in commodity prices; availability of financing; changes in economic and market conditions; environmental and regulatory risks; operating hazards; and other risks inherent in the mineral exploration industry. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290037 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – March 19, AAC Technologies Holdings Inc. (HKEX Stock Code: 2018) held its 2025 Annual Results Announcement Conference in Singapore and reported a strong set of annual results. The Group achieved RMB 31.82 billion in annual revenue, representing a 16.4% year-on-year increase and marking a record high of over RMB 30 billion, with net profit rising 39.8% to RMB 2.51 billion. These results reflect the continued success of the Company’s strategic transformation, with revenue reaching new highs in recent years and net profit delivering sustained double-digit growth.“Pioneering Innovation” and “AI Empowerment” have emerged as the central themes of AAC’s recent developments, driving its strategic transformation from a traditional component supplier to a builder of AI perception infrastructure.In an interview during the conference, AAC’s Chief Financial Officer, Guo Dan, highlighted that the Company’s strategic new business lines — represented by optics and automotive solutions — together with its expansion into high-potential AI sectors such as heat dissipation, robotics, and XR, have become the key growth engines supporting mid-to-long-term sustainable development. This strong momentum is expected to continue unlocking further growth potential in 2026.Looking ahead to 2026, Dan expressed strong confidence. Despite persistent industry volatility, the Group will capitalize on its diversified business portfolio to deliver steady revenue growth, with the growth rate expected to be no lower than that of 2025. At the same time, the gross profit margin is projected to improve steadily from the 22.1% baseline in 2025.( AAC Technologies CFO Guo Dan)1. On the Optics Business: Plastic Lens Gross Margin to Rise to 35%, with Proprietary WLG Technology Reaching Key MilestoneAs a core strategic growth driver, AAC’s optics business (AAC Optics) has achieved rapid development since in 2019. It reported RMB 5.73 billion in revenue in 2025, with a compound annual growth rate (CAGR) exceeding 32% over the past six years, establishing itself as a key pillar of the Group’s overall growth.Dan stated that in 2026, the optics business is expected to deliver steady revenue growth while further improving its gross margin. In 2025, the Company continued to upgrade its mid-to-high-end lens product mix, with the shipments of lens products with 6 or more elements accounting for over 18% of the total and seven-element (7P) lens shipments reaching 15 million units. Building on this foundation, the gross profit margin of plastic lenses is projected to rise from 30% in 2025 to 35% in 2026, reaching a industry-leading level.Notably, AAC has made a significant breakthrough in its globally proprietary Wafer-Level Glass (WLG) lens technology, reaching a key milestone. This advancement not only expands the scope of application scenarios but is also expected to drive a shift in the market landscape traditionally dominated by plastic lenses. Dan added, “In the future, whether in smartphones, automotive solutions, or emerging smart terminal devices, we will see more stable incremental growth that will inject long-term momentum into our business growth.”2. On the Automotive Solution Business: The "Second Growth Engine" Solidifies, with 2026 Revenue Expected to Grow by 15%-20%Through the acquisition of Premium Sound Solutions (PSS), AAC has rapidly established a core platform in the smart automotive solution sector, successfully developing a second growth engine for the Company.Dan revealed that following the acquisition of PSS in 2024 and the acquisitions of Chuguang and PSG in 2025, the Company has become a comprehensive system-level automotive solution provider, expanding its business from smartphones into the entire automotive domain. In 2025, the Company’s automotive acoustics business recorded revenue of RMB 4.12 billion, representing a year-on-year increase of 16.1%. This performance has positioned AAC among the world’s top-tier automotive audio system suppliers, second only to industry leaders such as Harman and Bose.Regarding the 2026 outlook for the automotive acoustics business, Dan stated that the segment is expected to maintain high double-digit growth of 15% to 20%, while keeping the gross margin stable. The Company’s automotive solution business has now achieved broad customer coverage both in China and overseas, including multiple Asian markets. This diversified regional presence is expected to provide steady and reliable support for both revenue and profit growth.3. On AI Sectors: Heat Dissipation Business Poised to Reach RMB 10 Billion, with Explorations in XR and Robotics Opening New FrontiersIf optics and automotive solutions represent the Company’s “core growth engines,” then business lines such as heat dissipation, robotics, and XR optical waveguides constitute the high-potential “reserves” for AAC’s future development. Dan noted that the Company’s revenue in the past was primarily driven by traditional mobile phone acoustics and haptics business. However, following years of strategic transformation and amid broader industry technological shifts, AI has become the fundamental driver underpinning the sustained growth of the Company’s multiple product lines.“For example, the rapid growth of the heat dissipation business is mainly attributable to AI-driven demand. Similarly, our initiatives in robotics and AR glasses are also propelled by AI,” Dan explained. In 2025, the Company’s heat dissipation business recorded revenue of RMB 1.67 billion, grew by 410.9% year-on-year. This performance has further solidified the Company’s position as one of the leading global suppliers in consumer electronics heat dissipation. “As AI technology continues to advance, related application scenarios are expected to extend from smartphones to a wider range of devices, including laptops and tablets, generating strong momentum for the Company’s overall growth.”The acquisition of Yuandi Technology, with more notable strategic significance, has allowed AAC to formally enter the data center liquid cooling, AI server heat dissipation, and high-end thermal solutions sectors, and extend its capabilities from “terminal-side heat dissipation” to “AI infrastructure heat dissipation” creating a synergistic “terminal + infrastructure” development model. Dan stated clearly, “Leveraging the substantial market opportunities across multiple sectors, our heat dissipation business has the potential to reach and even exceed a scale of RMB 10 billion in the coming years, positioning it as a highly promising and important growth engine for the Group.”In the XR optical waveguide field, through the acquisition of Dispelix — a global leader in AR diffractive waveguide technology — AAC has become one of the few industry players with vertically integrated capabilities spanning optical waveguide design and manufacturing. The Company can now offer one-stop full display module solutions, encompassing optical waveguides, optical engines, push-pull lenses, eye-tracking systems, and electrochromic technology. AAC is expected to become the world’s first supplier to achieve mass production of SRG full-color optical waveguides for leading customers in 2026. Dan disclosed, “The per-unit value in the optics business can reach USD 100–200. These initiatives are expected to deliver clear mass production and shipment opportunities within the next two to three years, continuously generating significant value in revenue, profit, and long-term market expansion.”Regarding the robotics field, Dan pointed out that the industry’s market definition, application scenarios, and product forms are still evolving and remain in a diverse exploratory stage. AAC has long maintained deep involvement and has established comprehensive layouts across multiple core areas, including acoustics, motors, optics, structural components, and electromechanics, laying a solid foundation to capture opportunities as the sector matures. “For example, our dexterous hand products for humanoid robots have already entered mass production and shipments, generating over RMB 100 million in revenue last year. In addition, we are co-developing the first motor, as a core component for AI hardware devices, with our customers. Overall, the Company has built deep cooperation with leading domestic and international customers, and we believe we will become an important player in this field in the future.”4. Strategic Review: Combining Technology Reuse with Ecosystem Construction to Anchor Long-Term GrowthIn AAC’s three-decade development journey, the core driver behind its sustained growth has consistently been rooted in the dual logic of technology reuse and ecosystem construction.Leveraging its long-established, robust technological foundations in micro-acoustics, precision optics, electromagnetic drives, sensors, and semiconductors, the Company has successfully upgraded and expanded its business, with its focus shifting from mobile phones and consumer electronics to emerging high-growth areas, including AI terminals, robotics, XR, smart vehicles, and data center infrastructure. This approach enables its core technological capabilities to be efficiently migrated and continuously amplified across diverse application scenarios.This development model — “upgrading application scenarios without changing underlying technology” — not only ensures the stability and success rate of business transformation but also allows the Company to rapidly address capability gaps through strategic ecosystem integration, such as the acquisitions of Dongyang, PSS, Chuguang, and Yuandi. Together, these efforts have created a virtuous cycle of “technology–product–scenario–customer.”The clear pathway to realizing this cycle was articulated by Dan in her outlook: Looking ahead to 2026 and beyond, AAC will position itself as a “builder of AI perception infrastructure,” deepen cross-business synergy and full-scenario coverage, accelerate its expansion into the “AI blue ocean,” strengthen its global footprint, and continue riding the wave of industry development to achieve new heights.source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 3月19日，瑞声科技（2018.HK）在新加坡举办2025年度业绩发布会，交出了亮眼的"年度答卷"。财报显示，瑞声科技2025年收入人民币318.2亿元，历史首次突破300亿元大关，同比增长16.4%。净利润达 25.1 亿元，同比大幅增长39.8%。公司近年来营收规模屡创新高，净利润实现高双位数增长，战略转型成效凸显。"向新而行"与"AI赋能"已成为瑞声科技近年发展的核心关键词，而这背后正是公司从元器件供应商向"AI感知基础设施构建者"的深刻转型。瑞声科技CFO郭丹在业绩发布会访谈中强调，以光学、车载为代表的战略新业务，叠加散热、机器人、XR 等AI蓝海赛道布局，已构建起公司中长期可持续增长的核心动力引擎，2026年将持续释放增长潜力。展望2026年，郭丹表示充满信心。尽管行业仍存在波动，集团将依托多元业务引擎，实现全年稳健的收入增长，增速预计不低于2025年的水平。同时，毛利率也将在2025年22.1%的基础上稳步提升。（受访者：瑞声科技CFO郭丹）01、谈光学业务：塑胶镜头毛利率将升至35%，独家WLG技术迎关键里程碑作为公司战略核心增长点，瑞声科技光学业务（辰瑞光学）自2019年确立布局以来实现跨越式发展。数据显示，光学业务2025年营收已攀升至57.3亿元，六年期间年均复合增长率（CAGR）超32%，成为集团增长的重要支柱。郭丹介绍，2026 年公司光学业务将实现稳健增长，毛利率亦同步提升。2025年，公司持续优化中高端镜头产品结构，6P及以上规格镜头出货占比突破18%，7片式镜头出货量达1500 万颗。在此基础上，2026年塑胶镜头毛利率将从2025 年的30% 提升至 35%，达到行业领先水平。值得关注的是，瑞声科技全球独家的WLG玻璃镜片技术实现历史性突破，迎来关键里程碑，不仅拓宽了应用场景边界，还有望重构全球塑胶镜头主导的市场格局。郭丹表示，"未来无论是手机、车载领域，还是新兴智能终端形态，都会看到更多更稳健的增量为业务增长注入长期动能。"02、谈车载业务："第二增长极"稳固，2026年营收预计增长15%-20%通过收购PSS 公司，瑞声科技快速搭建起智能车载领域的核心平台，成功培育出助推公司发展的"第二增长极"。郭丹透露，公司2024年完成PSS 收购，2025年并购初光、PSG，已全面升级为车载领域系统级解决方案提供商，业务版图从智能手机拓展至汽车全域。2025年公司车载声学业务收入达41.2亿元，同比增长16.1%，跻身仅次于Harman、Bose的全球头部车载音频系统供应商行列。针对车载声学业务2026年发展前景，郭丹表示，业务有望保15%-20%的高位双位数增长，毛利率将保持稳健。目前公司车载业务已实现海外、国内及亚洲多地客户的全面拓展，多区域布局将为营收与利润带来稳健且确定的增长支撑。03、谈AI蓝海业务：散热业务未来规模有望达百亿，XR、机器人再拓新局如果说光学、车载是公司的"核心增长引擎"，那么散热、机器人、XR光波导等业务则是瑞声科技布局未来的高潜"后备军"。郭丹认为，公司过往营收主要依托以传统手机声学与触觉等为代表的业务，而历经数年战略转型，叠加行业技术变革，AI已成为驱动公司多产品线持续成长的核心基石。"比如，散热业务增长为什么会这么快？主要还是来自于AI需求，包括机器人、AR眼镜的布局也是来自于AI需求。"郭丹介绍，2025年公司散热业务营收同比增长4倍至16.7亿元，稳居消费电子散热全球头部供应商地位。"未来随着AI持续发展，相关应用将从智能手机进一步延伸至笔电、平板等更多品类，实现更广泛的场景覆盖，为公司增长提供强劲动能。"而更具战略意义的是，通过收购远地科技，瑞声科技正式进军数据中心液冷、AI 服务器散热及高端热管理领域，实现从"终端散热"向"AI基建散热"的场景延伸，形成"终端+基建"双赛道协同发力的格局。郭丹明确表示："依托多业态带来的广阔市场机遇，我们的散热业务有望在未来几年间实现百亿级规模，成为集团极具潜力的重要增长引擎。"在XR光波导领域，瑞声科技通过收购全球领先的AR衍射光波导企业Dispelix，成为业内少数具备光波导设计与制造垂直整合能力的厂商，可提供光波导、光引擎、推/拉透镜、眼动追踪及电致变色等一站式全显示模组解决方案，并预计于2026年成为全球首家向头部客户量产SRG全彩光波导的供应商。郭丹透露，"光学业务单机价值量可达100–200美金，相关布局未来两三年内有望迎来明确量产出货机遇，将从营收、利润及长期市场增量等多方面持续创造显著价值。"针对机器人领域，郭丹指出，当前行业的市场定义、应用场景及产品形态尚未完全定型，仍处于多样化探索发展阶段。而瑞声科技长期深耕声学、马达、光学、结构件、电机等多个核心领域，并已完成深度布局，为把握行业成熟后的增长机遇筑牢基础。"比如，我们的人形机器人灵巧手相关产品已经批量出货，去年收入规模就超过了1亿元。另外，我们正在与客户开发第一款AI硬件设备中的核心零部件电机。整体来看，公司已与国内外头部客户都建立深度合作，相信未来会是其中的一个重要玩家。"04、战略复盘：技术复用+生态构建，锚定长期增长梳理瑞声科技三十载发展脉络，其持续增长的核心密码，始终根植于技术底座复用 + 生态协同构建的双重逻辑。依托在微型声学、精密光学、电磁传动、传感器及半导体领域长期积淀的硬核技术底座，公司成功实现从手机等消费电子主赛道，向AI终端、机器人、XR、智能汽车、数据中心基建等新兴领域的跨越升级，让核心技术能力在多元场景中高效迁移、持续放大。这种"底层技术不变，应用场景迭代"的发展模式，既保障了业务转型的稳定性与成功率，又通过生态整合（如收购东阳精密、PSS、初光、远地科技）快速补全能力短板，形成"技术-产品-场景-客户"的正向循环。而打通这一循环的关键路径，已在郭丹的展望中清晰呈现：面向2026年及未来，瑞声科技将锚定"AI感知基础设施构建者"定位，深化多业务协同与全场景覆盖，加速奔赴"AI蓝海"，深耕全球化布局，推动公司乘势而上、再攀高峰。source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务摘要截至2025年12月31日止年度(百万港元)20252024变动收入 4,001.13,811.9+ 5.0%毛利 1,385.11,312.1+ 5.6%毛利率34.6%34.4%+ 0.2个百分点本公司拥有人应占溢利 331.4201.0+ 64.9%纯利率 8.3%5.3%+ 3.0个百分点经调整EBITDA 622.8612.5+ 1.7%每股盈利（港仙） 31.7619.26+ 64.9%香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）今天公布截至2025年12月31日止年度之全年业绩。集团的收入由2024年的3,811.9百万港元按年增加5.0%至2025年的4,001.1百万港元，由于核心方便面业务持续增长、中国内地消费情绪改善及海外市场需求增加所致。毛利由2024年的1,312.1百万港元增加5.6%至2025年的1,385.1百万港元；毛利率由2024年的34.4%微升0.2个百分点至2025年的34.6%。由于集团透过优化销售组合及持续推行成本效益措施，有效纾缓成本压力，支持毛利率提升。本公司拥有人应占溢利大幅增加64.9%至331.4百万港元，相当于年内纯利率8.3%。溢利及盈利能力较去年大幅改善，乃由于营运效率提升以及上年度曾确认资产减值亏损之非现金费用。集团的每股基本盈利增至年内的31.76港仙，经调整EBITDA水平由2024年的612.5百万港元增加1.7%至2025年的622.8百万港元，相当于年内经调整EBITDA利润率15.6%（2024年：16.1%）。董事会建议派发末期股息每股15.88港仙，派息率为50.0%。各业务地区之业务回顾及前景年内，来自香港及其他地区业务的收入增加7.7%至1,658.7百万港元，主要由于香港方便面业务表现稳健及其他地区需求增加；分部业绩上升16.1%至152.8百万港元，主要由于高端方便面销量持续增长。同时，中国内地业务于年内录得收入2,342.4百万港元，温和增长3.1%；分部业绩增加3.5%至339.9百万港元，主要由于集团持续致力拓展内陆地区销量，以及中国内地业务的销售势头持续。在香港，为持续丰富方便面产品组合，公司推出多款新单品，包括合味道杯面京都鸡白汤味及咚兵卫肉汁味杯乌冬（方便面）。为推动销量及促进消费者互动，合味道及出前一丁与虚拟歌手「初音未来」合作。此外，公司亦透过指定微信小程式加强餐饮渠道的数码化营销。为配合针对冷冻食品业务的高端化策略，公司推出日清The Chef’s Signature系列，以满足追求在家享受高质极致美食体验之消费者需求。公司持续扩大非面类产品组合，以时令产品加强其饮料产品线，以及推出全新一口装日清迷你可可脆。此外，香港制造的日清谷物麦片及鲜切蔬菜持续获得注重健康的消费者青睐，展现本公司对于健康、养生及营养的坚定承诺。在海外市场，集团在推行策略市场扩展及提升品牌方面取得重大进展。越南仍为东南亚快速增长的经济体之一，公司透过拓展其销售及分销渠道至现代零售渠道，并以新产品锁定年轻消费者群体把握强劲的消费者需求。台湾方面，公司在当地成立全资附属公司，为合作伙伴提供更清晰的销售方向及加强对他们的支援，促进销售动力及长期业务增长。韩国方面，随着韩流在全球的热潮日益扩张，韩国业务取得稳健表现。集团亦凭借其全球销售网络，将Gaemi Food Co. Ltd.（「Gaemi Food」）的零食产品推广至新的海外市场。在澳洲，公司加强与ABC Pastry Holdings Pty Ltd（「ABC Pastry」）的营运整合，同时把握主流及亚洲零售渠道对亚洲美食日益增长的兴趣，拓阔公司的方便面产品销售网络。在中国内地，公司的表现稳健，主要由于方便面销量扩张，以及公司策略性扩展内陆地区的业务据点。为提升消费者参与度及品牌知名度，公司增加店内试食活动、加强微信小程式等平台的数码化营销，并与日本虚拟歌手「初音未来」高调合作，加强促销活动。作为高端化策略的一部分，公司为丰富其产品组合，推出了日清咚兵卫油豆腐炸乌冬面杯面等新产品。非面类业务亦录得正面发展；分销业务扩大了产品组合，新增欧洲瓶装水、日本碳酸饮料以及日本巧克力及曲奇饼等高端进口产品，而零食业务则受惠于其薯片及节日产品，例如限量版可可脆粒等，取得良好表现。为展现对中长期发展的坚定承诺，集团以总代价人民币30.68百万元收购了两块珠海地块的土地使用权。集团计划投资超过人民币240百万元收购该等地块，于该等地块上建设新厂房及安装新生产线。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示：「我们对公司的增长前景保持谨慎乐观的态度，同时持续专注于成本控制和运营效率。全球经济复苏之路崎岖不平，主要由于地缘政治局势紧张及保护主义抬头导致供应链重组。在此背景下，集团仍将致力于在需求明确且具可持续性的市场中，持续推动产品升级及强化执行能力。香港政府的相关举措可望支撑经济及家庭开支，为我们产品组合持续高端化提供更有利的环境。中国内地的中产阶级不断壮大为我们带来巨大机遇，而越南蓬勃发展的零售业以及韩国对健康的关注亦将支持公司战略发展。此外，澳洲对高品质冷冻食品的需求不断上升，亦具有宝贵的增长潜力。我们透过高端化及多元化策略，增强在这些地区的竞争力。凭借稳健的财务状况、现金流生成能力及强大的品牌认受性，在中期至长期内我们将具备良好条件实现收入及盈利持续增长。」有关日清食品有限公司日清食品有限公司（「日清食品」，连同其附属公司统称「集团」；股份代号：1475）为一间在中国内地及香港知名的食品公司，主要专营优质方便面市场，旗下众多品牌不仅知名度高，且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」，以及多元化的家庭食品品牌组合，出品具标志性和优质的方便面、优质冷冻食品（包括冷冻点心及冷冻面条）并销售和分销其他食品及饮料产品（包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品）。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面，集团以创新技术推出「ECO杯」概念，销售活动主要集中在中国内地的一线及二线城市。此外，日清食品在其他地区开展业务，包括越南、台湾、韩国及澳洲市场。日清食品被纳入5项恒生指数，包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通食品饮料消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26 , 2026 - (ACN Newswire via SeaPRwire.com) – On March 25, CALB (03931.HK) rolled off the production line of the advanced R46 cylindrical battery system at its Chengdu factory, set to power the XPENG ARIDGE X3-F (Land Aircraft Carrier) flying car. According to sources, this power battery product utilizes CALB’s first-unveiled R46 cylindrical battery system technology. Boasting an energy density of 360Wh/kg, the battery stands as the highest-density solid-liquid hybrid cylindrical battery in the industry. It achieves an exceptional balance between high safety, high power density, and high energy density, and will be equipped in several of ARIDGE’s flying car models.The partnership between the two parties began in 2022, with CALB assisting ARIDGE in completing the world’s maiden flight of an electric vertical take-off and landing (eVTOL) flying car. Following a series of rigorous validations, the reliability of CALB’s battery products has been fully verified. Building on this momentum, CALB assembled a team of top researchers to focus on the next-generation advanced R46 cylindrical battery system, tasked with addressing a range of scientific and technological challenges. Furthermore, by taking the lead in collaborating with leading institutions including ARIDGE, the company has been awarded support from the National Key R&D Program Project, further positioning the technologies at the forefront of global innovation in intrinsic safety and high-specific-energy aviation power batteries. Consequently, the two parties have signed a deepened strategic cooperation agreement in April 2025, establishing an exclusive supply relationship for next-generation models.From leading the National Key R&D Program focused on advanced R46 cylindrical battery system technology to achieving mass production of flying car batteries, CALB is accelerating its expansion into forward-looking emerging sectors. The company’s commercialization capabilities across diversified application scenarios continue to strengthen, opening new growth opportunities in the competition for next-generation energy technologies. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com